Halozyme Therapeutics | HALO - Pre Utilidad Fiscal





Pre Utilidad Fiscal Cambio Fecha
Acadia Pharmaceuticals USD 3.98M 22.34M 2026-03
Agios Pharmaceuticals USD -99.11M 9.94M 2026-03
Alnylam Pharmaceuticals USD 221.65M 60.52M 2026-03
Amarin USD -852K 7.26M 2025-12
Amgen USD 1.51B 2.41B 2025-12
Baxter International USD -756M 877M 2025-12
Cara Therapeutics USD -4.91M 3.17M 2025-03
Cytokinetics USD -206.03M 23M 2026-03
DBV Technologies USD -33.16M 8.6M 2025-09
Eli Lilly USD 8.27B 1.03B 2025-12
Esperion Therapeutics USD 63.67M 95M 2025-12
Halozyme Therapeutics USD 180.33M 281.18M 2026-03
Intrexon USD -60.48M 27.09M 2024-06
Ionis Pharmaceuticals USD -93M 135M 2026-03
MannKind USD -16.37M 4.56M 2026-03
Minerva Neurosciences USD 22.51M 30.74M 2024-09
Nektar Therapeutics USD -34.7M 2.35M 2025-12
Pfizer USD 5.18B 6.82B 2026-03
Rigel Pharmaceuticals USD -1.03M 7.22M 2024-06
United Therapeutics USD 444M 6M 2025-12
Vanda Pharmaceuticals USD -22.92M 16.68M 2024-12